¾«¶«Ó°Òµ

• For Print
• April 24, 2024

¾«¶«Ó°Òµ. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI^® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the revenue in the third quarter of fiscal year 2023 (October 1, 2023 – December 31, 2023).

This information is being disclosed in conjunction with today's announcement of the first quarter 2024 results of Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai’s financial results for the fiscal year ended March 31, 2024, including details of LEQEMBI’s revenue, will be disclosed in Eisai's financial disclosure scheduled on May 15, 2024.

¾«¶«Ó°Òµserves as the lead of lecanemab development and regulatory submissions globally with both ¾«¶«Ó°Òµand Biogen Inc. co-commercializing and co-promoting the product and ¾«¶«Ó°Òµhaving final decision-making authority.

&²Ô²ú²õ±è;〶Ä

&²Ô²ú²õ±è;〶Ä

Media Inquiries:

Public Relations Department,

¾«¶«Ó°Òµ.

+81-(0)3-3817-5120

&²Ô²ú²õ±è;〶Ä　

• Full text